Terry A Jacobson Selected Research

Rhabdomyolysis

1/2019	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.
3/2013	Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
9/2010	Evidence-based management of statin myopathy.
11/2008	Fluvastatin, rhabdomyolysis, and myotoxicity.
6/2008	Managing dyslipidemia in chronic kidney disease.
6/2008	Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.
8/2007	The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
3/2007	Safety considerations with gastrointestinally active lipid-lowering drugs.
4/2006	Statin safety: lessons from new drug applications for marketed statins.
4/2006	Statin safety: an assessment using an administrative claims database.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Terry A Jacobson Research Topics

Disease

43	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2004
24	Dyslipidemias (Dyslipidemia) 07/2020 - 01/2006
23	Coronary Disease (Coronary Heart Disease) 09/2021 - 01/2003
17	Muscular Diseases (Myopathy) 04/2017 - 03/2003
15	Hypertriglyceridemia 01/2022 - 05/2007
14	Diabetes Mellitus 01/2020 - 04/2008
14	Rhabdomyolysis 01/2019 - 03/2003
12	Stroke (Strokes) 01/2022 - 04/2008
11	Myalgia 01/2018 - 08/2007
9	Myocardial Infarction 01/2022 - 12/2005
7	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 05/2007
7	Obesity 03/2016 - 10/2010
6	Atherosclerosis 08/2022 - 08/2008
5	Hypercholesterolemia 09/2021 - 11/2004
5	Inflammation (Inflammations) 01/2020 - 01/2010
5	Hyperlipidemias (Hyperlipidemia) 10/2016 - 03/2003
4	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 07/2017 - 11/2013
4	Chronic Disease (Chronic Diseases) 11/2013 - 01/2006
4	Coronary Artery Disease (Coronary Atherosclerosis) 08/2007 - 05/2003
3	Heart Failure 01/2022 - 08/2010
3	Hemorrhage 11/2021 - 08/2010
3	Atrial Fibrillation 11/2021 - 04/2017
3	Unstable Angina 11/2021 - 04/2005
3	Hypertension (High Blood Pressure) 07/2016 - 11/2013
3	Acquired Immunodeficiency Syndrome (AIDS) 05/2016 - 03/2010
3	Myotoxicity 11/2008 - 04/2006
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2019 - 01/2018
2	Cognitive Dysfunction 01/2019 - 12/2018
2	Cataract (Cataracts) 01/2019 - 01/2018
2	Prediabetic State (Prediabetes) 01/2018 - 04/2017
2	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 04/2017 - 05/2015
2	Pancreatitis 01/2014 - 09/2012
2	Cardiac Arrhythmias (Arrythmia) 06/2008 - 08/2006
2	Type 2 Diabetes Mellitus (MODY) 06/2008 - 05/2007
2	Renal Insufficiency (Renal Failure) 03/2007 - 05/2003
2	Ischemia 08/2006 - 04/2005
1	Infarction (Infarctions) 01/2022

Drug/Important Bio-Agent (IBA)

59	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 03/2003
41	LipidsIBA 09/2021 - 03/2003
24	LDL CholesterolIBA 12/2021 - 05/2003
19	Triglycerides (Triacylglycerol)IBA 09/2021 - 01/2006
16	CholesterolIBA 08/2022 - 05/2007
13	oxidized low density lipoproteinIBA 08/2022 - 08/2007
13	eicosapentaenoic acid ethyl esterIBA 01/2022 - 06/2012
13	HDL CholesterolIBA 07/2017 - 01/2006
11	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020 - 01/2003
7	Lipoproteins (Lipoprotein)IBA 09/2021 - 09/2014
7	Pharmaceutical PreparationsIBA 11/2013 - 03/2003
6	Fibric Acids (Fibrates)IBA 09/2009 - 03/2003
5	Niacin (Nicotinic Acid)FDA LinkGeneric 08/2011 - 03/2003
5	Fluvastatin FDA Link 11/2008 - 05/2003
5	Oxidoreductases (Dehydrogenase)IBA 06/2008 - 11/2004
5	Coenzyme A (CoA)IBA 06/2008 - 03/2003
4	Biomarkers (Surrogate Marker)IBA 08/2022 - 09/2011
4	Fish OilsIBA 04/2017 - 12/2005
4	VitaminsIBA 03/2016 - 03/2007
4	Bile Acids and Salts (Bile Acids)IBA 01/2016 - 03/2007
4	cerivastatin (Kazak)FDA Link 03/2013 - 05/2003
3	Lipoprotein(a)IBA 08/2022 - 11/2013
3	Ezetimibe (Zetia)FDA Link 06/2017 - 03/2007
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 04/2017 - 01/2003
3	Proteins (Proteins, Gene)FDA Link 03/2016 - 01/2016
3	CarbohydratesIBA 03/2016 - 01/2016
3	Trace Elements (Biometals)IBA 03/2016 - 01/2016
3	FatsIBA 03/2016 - 01/2016
3	Hormones (Hormone)IBA 03/2016 - 01/2016
3	MineralsIBA 03/2016 - 01/2016
3	ApolipoproteinsIBA 01/2016 - 11/2012
3	HDL LipoproteinsIBA 11/2012 - 09/2011
2	HomocysteineIBA 08/2022 - 03/2007
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 10/2010
2	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 04/2008
2	Eicosapentaenoic AcidIBA 04/2017 - 12/2005
2	Docosahexaenoic AcidsIBA 04/2017 - 12/2005
2	evolocumabIBA 10/2016 - 01/2016
2	Simvastatin Drug Combination Ezetimibe (Vytorin)FDA Link 03/2016 - 05/2015
2	Immunologic Factors (Immunomodulators)IBA 01/2016 - 01/2016
2	Atorvastatin (Lipitor)FDA Link 03/2013 - 12/2008
2	Apolipoproteins B (ApoB)IBA 11/2012 - 08/2011
2	Fatty Acids (Saturated Fatty Acids)IBA 09/2011 - 01/2006
2	Rosuvastatin Calcium (Crestor)FDA Link 10/2010 - 04/2006
2	fenofibric acid FDA Link 10/2010 - 09/2009
2	ProstaglandinsIBA 08/2010 - 04/2010
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2010 - 04/2010
2	Gemfibrozil (Lopid)FDA LinkGeneric 09/2009 - 01/2006
2	Fenofibrate (CiL)FDA LinkGeneric 09/2009 - 01/2006
2	Pravastatin (Pravachol)FDA LinkGeneric 04/2008 - 05/2003
2	CreatinineIBA 08/2007 - 03/2007
2	Cytochrome P-450 CYP3AIBA 04/2006 - 05/2003
1	Interleukin-6 (Interleukin 6)IBA 08/2022
1	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 08/2022
1	C-Reactive ProteinIBA 08/2022
1	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 08/2022

Therapy/Procedure

42	Therapeutics 01/2022 - 03/2003
10	Secondary Prevention 12/2018 - 01/2003
6	Drug Therapy (Chemotherapy) 01/2016 - 05/2007
3	Medication Reconciliation 05/2016 - 03/2010
3	Bariatric Surgery 03/2016 - 01/2016
3	Blood Component Removal (Apheresis) 01/2016 - 11/2013
2	Polypharmacy 09/2010 - 05/2003